The effect of interventions targeting gut microbiota on depressive symptoms: a systematic review

Abstract Background: Despite their popularity, the efficacy of interventions targeting gut microbiota to improve depressive symptoms is unknown. Our objective is to summarize the effect of microbiome-targeting interventions on depressive symptoms. Methods: We conducted a systematic review and meta-analysis. We searched MEDLINE, Embase, PsycINFO, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews and […]

The safety and efficacy of fecal microbiota transplantation in a population with bipolar disorder

The safety and efficacy of fecal microbiota transplantation in a population with bipolar disorder during depressive episodes: study protocol for a pilot randomized controlled trial Abstract Background: Bipolar disorder (BD) is a chronic, debilitating illness with significant medical morbidity, often secondary to current treatments, and a high recurrence rate. This burden of disease reflects limitations in […]

Changes in the gut microbiome associated with infliximab in patients with bipolar disorder

Objectives: Available information exists supporting the gut-brain axis, but additional information is needed to explore how the gut microbiome changes when exposed to mood disorder treatments. We sought to explore the effects of a novel treatment for bipolar disorder (BD), infliximab, on the gut microbiome. Methods: Participants with a primary diagnosis of BD (n = 15) who […]

The microbiome and mental health: Hope or hype?

The biggest predictor of future behaviour is past behaviour, but in science we at times seem remarkably unable to learn from past experiences. Take the furor regarding the gut microbiome, especially as it pertains to mental illness. Less than 10 years ago the concept of microbial manipulation to treat mental illness was primarily hypothetical, yet […]

Receive the latest news

Join Our Journey

Be the First to Know: Unlock exclusive updates on the progress and launch timeline of our groundbreaking biotherapeutics product development.

Name(Required)

Asem Bala

MSc

Asem Bala, MSc has over 20 years of experience in Healthcare & Clinical Research Management, now working at Taylored Biotherapeutics to create partnerships and ensure regulatory approvals.

Dr. Valerie Taylor

MD, PhD, FRCP

Dr. Valerie Taylor, MD, PhD, FRCP is a Professor of Psychiatry at the University of Calgary. She completed a Bachelor of Medical Science and graduated from medical school at Memorial University of Newfoundland. She subsequently finished her residency training in Psychiatry and got her PhD in Neuroscience from McMaster University in Hamilton, Ontario. Prior to coming to Calgary, she was the chief of Psychiatry at the Women’s College Hospital and the chief of Adult Health Services at the Center for Addiction and Mental Health in Toronto.

Her academic focus has been on the area of medical psychiatry – specifically, for the last 5 years, on the gut brain axis and the the gut microbiome. She is the only funded researcher in North America examining the therapeutic effects of fecal transplant as a treatment for mental health and she currently has 4 novel clinical trials looking at modifying the gut microbiome to treat mood disorders as well as the largest biological neuroscience microbiome repository in North America. She has over 180 peer reviewed publications and funding from a variety of national and international funding agencies. In 2020 she started Taylored Biotherapeutics, a micro therapeutics drug company. Today her primary role is in leading product development, getting regulatory approval, and finding partnerships.